伊立替康联合顺铂和(或)洛铂二线治疗广泛期小细胞肺癌的疗效分析

Efficacy of irinotecan plus cisplatin/lobaplatin as the second-line therapy for extensive stage small cell lung cancer

目的比较伊立替康联合顺铂和伊立替康联合洛铂方案二线治疗广泛期小细胞肺癌的客观疗效及不良反应。方法回顾分析2011年1月至2013年12月间内蒙古包头市肿瘤医院收治的56例复发转移的小细胞肺癌的临床资料,根据患者接受不同治疗方案分为伊立替康联合顺铂方案(IP组)和伊立替康联合洛铂方案(IL)组,每组28例。记录临床近期疗效及治疗3周后的不良反应。结果 IP组有效率为28.6%,疾病控制率为57.1%。IL组有效率为25.0%,疾病控制率为60.7%,两组相比,差异无统计学意义(P>0.05)。IL组胃肠道不良反应明显低于IP组,差异有统计学意义(P<0.05)。结论伊立替康联合顺铂和(或)洛铂二线治疗广泛期小细胞肺癌具有较高的临床有效率,联合洛铂不良反应较轻。

Objective To compare the efficacy and adverse reactions of irinotecan plus cisplatin with irinotecan plus lobaplatin as the second-line therapy for extensive stage small cell lung cancer. Methods Retrospectively analyze the clinical data of 56 patients with relapsed and metastatic small cell lung cancer treated at Tumor Hospital of Baotou from January 2011 to December 2013. The patients were divided into irinotecan combined with cisplatin（ IP） group and rinotecan combined with lobaplatin（ IL） group according to the therapy regimens,with 28 patients in each group. The short-term efficacy and adverse reactions at 3 weeks after treatment were recorded. Results In IP group,the efficacy rate was 28. 6% and the disease control rate was 57. 14%. In IL group,the efficacy rate was 25. 0% and the disease control rate was60. 7%（ P 〉 0. 05）. The gastrointestinal reactions were significantly less in IL group compared with IP group（ P 〈 0. 05）. Conclusion Irinotecan combined cisplatin / lobaplatin regimens show high clinical efficacy and the combination with lobaplatin shows less adverse reactions.